Perseverance Capital

Galactic Holdings is a digital finance platform that provides a comprehensive suite of products designed to facilitate cryptocurrency transactions. The company offers TruBit, which delivers convenient fiat on/off ramps and payment solutions tailored for the Latin American market. Additionally, it operates TruBit Pro, an advanced trading exchange, and Moneta, a stablecoin pegged to the Mexican peso. Galactic Holdings aims to create an all-in-one ecosystem that includes a crypto wallet and exchange, enabling users to easily access and utilize cryptocurrencies for various purposes such as trading, remittance, and payments.

MindRhythm is a medical device company dedicated to improving the diagnosis, triage, and management of stroke and concussion patients through innovative biometrics. The company has developed proprietary monitoring devices and a communication platform that offer real-time visibility into critical situations, both prehospital and in the operating room. This technology empowers clinicians to intervene promptly and accurately, significantly reducing the risk of brain damage in patients experiencing neurological emergencies. By focusing on enhancing patient outcomes in acute care settings, MindRhythm aims to transform the approach to neurological injury prevention and management.

CG Oncology, formerly known as Cold Genesys, is a privately held clinical-stage biopharmaceutical company specializing in the development of innovative oncolytic immunotherapies aimed at treating cancer. The company focuses on creating therapies that offer alternatives to conventional cancer treatments, particularly for patients with bladder cancer. Its lead candidate, cretostimogene grenadenorepvec, is a targeted intravesical immunotherapy agent designed to be delivered directly to the bladder. Currently, CG Oncology is conducting multiple clinical trials, including two phase three trials addressing high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC), as well as a phase two study in combination with a checkpoint inhibitor for high-risk NMIBC. Through its research and clinical endeavors, CG Oncology aims to provide effective and less invasive treatment options for bladder cancer patients.

CG Oncology, formerly known as Cold Genesys, is a privately held clinical-stage biopharmaceutical company specializing in the development of innovative oncolytic immunotherapies aimed at treating cancer. The company focuses on creating therapies that offer alternatives to conventional cancer treatments, particularly for patients with bladder cancer. Its lead candidate, cretostimogene grenadenorepvec, is a targeted intravesical immunotherapy agent designed to be delivered directly to the bladder. Currently, CG Oncology is conducting multiple clinical trials, including two phase three trials addressing high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC), as well as a phase two study in combination with a checkpoint inhibitor for high-risk NMIBC. Through its research and clinical endeavors, CG Oncology aims to provide effective and less invasive treatment options for bladder cancer patients.

NxThera, founded in 2008 and headquartered in Maple Grove, Minnesota, specializes in the development of medical technologies for treating endourological conditions. The company's core technology involves convective water vapor energy, designed to deliver minimally invasive, thermal therapy for conditions such as benign prostatic hyperplasia (BPH), which affects over 32 million men in the U.S. As of April 30, 2018, NxThera operates as a subsidiary of Boston Scientific Corporation.